AusBiotech says the industry should not be made to pay for the TGA's digital transformation through increases to cost recovery fees.
AusBiotech says it cannot support new reason for higher cost-recovery fees
March 1, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Draft 'National Health Genomics Policy Framework' out for consultation
July 3, 2025 - - Latest News -
MedAdvisor announces agreement confirming the sale of Australian business
July 3, 2025 - - Latest News -
GBMA announces planned departure of long-standing CEO
July 2, 2025 - - Latest News -
Neurizon announces global agreement with Elanco for the commercialisation of NUZ-001
July 2, 2025 - - Australian Biotech -
Prescient Therapeutics opens share purchase plan
July 2, 2025 - - Australian Biotech -
Amplia Therapeutics announces additional confirmed partial response recorded in ACCENT trial
July 2, 2025 - - Australian Biotech -
Island Pharmaceuticals announces the appointment of new chair
July 2, 2025 - - Australian Biotech